Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study

  1. Nasamon Wanlapakorn
  2. Nungruthai Suntronwong
  3. Harit Phowatthanasathian
  4. Ritthideach Yorsaeng
  5. Preeyaporn Vichaiwattana
  6. Thanunrat Thongmee
  7. Chompoonut Auphimai
  8. Donchida Srimuan
  9. Thaksaporn Thatsanatorn
  10. Suvichada Assawakosri
  11. Sitthichai Kanokudom
  12. Yong Poovorawan

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1080/21645515.2022.2029111
  2. ScreenIT

    SciScore for 10.1101/2021.11.04.21265908: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: The study protocols were approved by the Institutional Review Board (IRB) of the Chulalongkorn University Faculty of Medicine (IRB numbers 192/64 and 491/64).
    Consent: Written informed consent was obtained from all participants prior to collecting clinical data and samples.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Experimental Models: Cell Lines
    SentencesResources
    Vaccination and blood collection: CoronaVac (Sinovac Life Sciences, Beijing, China) is an inactivated virus vaccine created from African green monkey kidney cells (Vero cells) that have been inoculated with SARS-CoV-2 (CZ02 strain).
    Vero
    suggested: None
    Software and Algorithms
    SentencesResources
    antinucleocapsid (anti-N) IgG was tested using the commercially available automated ARCHITECT system (Abbott Diagnostics, Abbott Park, IL) by chemiluminescent microparticle immunoassay (CMIA).
    Abbott
    suggested: (Abbott, RRID:SCR_010477)
    The graphical presentations were prepared using GraphPad Prism version 9.0 software (
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)
    The statistical analysis was performed using IBM SPSS Statistics for Windows, version 21 (IBM Corp., Armonk, NY)
    SPSS
    suggested: (SPSS, RRID:SCR_002865)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.11.04.21265908v3 on medRxiv
  4. Version published to 10.1101/2021.11.04.21265908v2 on medRxiv
  5. Version published to 10.1101/2021.11.04.21265908v1 on medRxiv